Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Summary

Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses

Timeline

Start

2003-11

Primary completion

2006-02

Completion

—

Drugs

Indications